Development of classification criteria for discoid lupus erythematosus: Results of a Delphi exercise - 14/12/17
Abstract |
Background |
No classification criteria currently exist for discoid lupus erythematosus (DLE), which has led to problematic heterogeneity in both observational and interventional research efforts.
Objectives |
We sought to develop DLE classification criteria based on consensus of international expert opinion of relevant stakeholders in the field.
Methods |
Using a Delphi consensus process and nominal group techniques, potential items for classification criteria were generated. Experts ranked items in terms of their appropriateness and ability to discriminate DLE from other diagnoses, and items were subsequently eliminated using consensus exercises.
Results |
A final list of 12 clinical and histopathologic items was generated for potential inclusion into a set of DLE classification criteria through a formal ongoing validation process.
Limitations |
The participants are predominantly composed of DLE experts in North America and Europe.
Conclusion |
This work represents a key step toward the development of formal DLE classification criteria.
Le texte complet de cet article est disponible en PDF.Key words : classification criteria, connective tissue diseases, cutaneous lupus erythematosus, Delphi method, discoid lupus erythematosus, lupus
Abbreviations used : ACR, CLE, DLE, EULAR, NGT
Plan
Drs Werth and Merola are co-senior authors. |
|
Supported by the Department of Veterans Affairs (Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development to Dr Werth) and departmental funds from the Brigham and Women's Hospital Department of Dermatology. Celgene supported our meeting at the World Congress of Dermatology 2015. |
|
Disclosure: Dr Merola is a consultant for Biogen IDEC, Amgen, AbbVie, and Eli Lilly, and licensed a questionnaire to AbbVie. He has received grants from Biogen IDEC. Dr Szepietowski is a consultant for AbbVie, Biogenetica International Laboratories, LEO Pharma, Merck-Serono, Novartis, Pierre-Fabre, Sandoz, and Toray Corporation, and is a speaker for AbbVie, Astellas, Actavis, Adamed, Berlin-Chemie Mennarini, Bioderma, Fresenius, Janssen-Cilag, LEO Pharma, Takeda, and Vichy. Dr Nyberg is a consultant for Biogen. Dr Dutz is a consultant and speaker for Janssen-Ortho, AbbVie, Amgen, LEO Pharma, Celgene, Roche, and Novartis, and has received grants from AbbVie and Celgene. Dr Goodfield is a consultant for AbbVie, Janssen, Novartism, and Celgene, and is a speaker for AbbVie, Janssen, and LEO Pharma. He has received funding from Janssen, Pfizer, Novartis, LEO Pharma, and AbbVie. Dr Werth is a consultant for Biogen, Resolve Therapeutics, Celgene, Janssen, Genentech, Idera, Principia, Pfizer, Momenta, Medimmune, Xoma, Cipher, Lilly, TGMallincrodt, and Syntimmune. She has received grants from Biogen, Celgene, Genentech, Janssen, and Corbus Pharmaceuticals. Drs Elman, Joyce, Furukawa, Hasegawa, and Marinovic have no conflicts of interest to declare. |
Vol 77 - N° 2
P. 261-267 - août 2017 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?